UNSPSC 51182216: Carboprost methyl

This classification denotes a prostaglandin analogue C22H38O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UVV9BU3089, chemically known as prosta-5,13-dien-1-oic acid, 9,11,15-trihydroxy-15-methyl-, methyl ester, (5z,9.alpha.,11.alpha.,13e,15s)-, but more generally known as carboprost methyl, which bears US NIH Compound Identifier 5283105. Most nations, for tariff and trade purposes, schedule carboprost methyl under HS 29375000 and SITC 54156. As of Q4 2014, CARBOPROST METHYL remains US FDA's Preferred Term for this commodity.

SMILES: CCCCC[C@@](C)(/C=C/[C@H]1[C@@H](C[C@@H]([C@@H]1C/C=C\CCCC(=O)OC)O)O)O.

UNSPSC 51182216 Carboprost methyl is a Commodity code encompassing pharmaceutical products supplied through state and local multistate cooperative purchasing agreements. State and local governments procure active pharmaceutical ingredients and finished dosage forms under this code primarily through aggregated, multi-source supplier agreements managed by cooperative purchasing alliances rather than through direct jurisdiction-level solicitations. The issuing bodies are state procurement offices administering multistate cooperative purchasing vehicles, which bundle pharmaceutical demand across participating state agencies, local government facilities, and in some cases subordinate jurisdictions in other states.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal (RFP) on January 20, 2026 (S1070000015802) to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products effective July 1, 2026, with proposals due March 26, 2026. The solicitation requires vendors to supply products through three authorized wholesalers, certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, and maintain contractual relationships with at least two of the three wholesalers with chargeback systems in place. Pricing will be weighted at 75 percent of evaluation, with the remainder distributed across fixed pricing (10 percent), price competitiveness structures, EDI capability, and administrative compliance. Vendors must carry commercial general liability insurance of $5,000,000 per occurrence and network security and privacy liability of $2,000,000, and all products must comply with FDA requirements and possess a minimum six-month shelf life. MMCAP reserves the right to make sole, dual, or multi-awards based on therapeutic considerations and member-specific needs, with contract terms of two years for new responders and optional extensions at MMCAP's discretion.